



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



BAY-1082439

Item No. 35456

CAS Registry No.: 1375469-38-7
Formal Name: N-[2,3-dihydro-8-[(2R)-2-hydroxy-3-(4-morpholinyl)propoxy]-7-methoxyimidazo[1,2-c]quinazolin-5-yl]-2-methyl-3-pyridinecarboxamide
MF: C₂₅H₃₀N₆O₅
FW: 494.6
Purity: ≥98%
UV/Vis.: λ_{max}: 227, 275 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BAY-1082439 is supplied as a solid. A stock solution may be made by dissolving the BAY-1082439 in the solvent of choice, which should be purged with an inert gas. BAY-1082439 is soluble in DMSO.

Description

BAY-1082439 is an inhibitor of PI3K α , PI3K β , and PI3K δ (IC₅₀s = 5, 15, and 1 nM, respectively).¹ It is selective for PI3K α , - β , and - δ over PI3K γ (IC₅₀ = 52 nM). BAY-1082439 selectively inhibits proliferation of *PTEN*-null LNCaP and PC3 prostate cancer cells over wild-type *PTEN* isogenic PC3 cells. BAY-1082439 (75 mg/kg) decreases intratumoral levels of phosphorylated Akt and reduces tumor growth in a mouse model of castration-resistant prostate cancer using castrated *Pten* conditional knockout mice (*Pten*-null mice). Intermittent administration of BAY-1082439 (180 mg/kg) reverses resistance to an anti-PD-1 antibody and induces CD8⁺ T cell clonal expansion and T cell-mediated inflammation in the tumor microenvironment in castrated *Pten*-null mice.²

References

1. Zou, Y., Qi, Z., Guo, W., et al. Cotargeting the cell-intrinsic and microenvironment pathways of prostate cancer by PI3K $\alpha/\beta/\delta$ inhibitor BAY1082439. *Mol. Cancer Ther.* **17**(10), 2091-2099 (2018).
2. Qi, J., Xu, Z., Zhang, L., et al. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3K $\alpha/\beta/\delta$ treatment. *Nat. Commun.* **13**(1), 182 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/12/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM